Latest Articles

Publication Date
SPP1 as a key modulator of M2 macrophage polarization promotes endometriosis progression via activation of the FAK/PI3K/AKT pathway: A bioinformatics and experimental study.

Endometriosis (EMs) is a gynecological disorder characterized by chronic inflammation and an aberrant immune microenvironment. In this study, we integrated the GSE6364 dataset from the GEO database to identify differentially …

Published: Sept. 17, 2025, midnight
Integrated GNPS, semi-preparative HPLC, and network pharmacology reveal active ingredients and potential machenisms of Paeonia suffruticosa Andr. leaves in treating endometriosis with anxiety/depression.

Endometriosis (EMs) with anxiety/depression is a common comorbidity of EMs, yet effective treatments are still lacking. Leaves of Paeonia suffruticosa Andr. (PSL) have potential therapeutic effects on EMs and their …

Published: Sept. 15, 2025, midnight
Endometrial cancer drug Rina-S wins FDA's breakthrough therapy designation - Rare Cancer News

Endometrial cancer drug Rina-S wins FDA's breakthrough therapy designation Rare Cancer News

Published: Sept. 10, 2025, 12:49 p.m.
Genmab (CPSE:GMAB) Is Up 10.3% After FDA Breakthrough for Rina-S in Endometrial Cancer – Has The Bull Case Changed? - Yahoo Finance

Genmab (CPSE:GMAB) Is Up 10.3% After FDA Breakthrough for Rina-S in Endometrial Cancer – Has The Bull Case Changed? Yahoo Finance

Published: Sept. 6, 2025, 11:31 a.m.
Correction: Blocking GATA6 Alleviates Pyroptosis and Inhibits Abdominal Wall Endometriosis Lesion Growth Through Inactivating the PI3K/AKT Pathway.

Published: Sept. 5, 2025, midnight
Pain Scores Drop from 8/10 to Zero: IceCure's ProSense Shows Breakthrough Results in Endometriosis Treatment - Stock Titan

Pain Scores Drop from 8/10 to Zero: IceCure's ProSense Shows Breakthrough Results in Endometriosis Treatment Stock Titan

Published: Sept. 4, 2025, 12:30 p.m.
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. - AInvest

Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. AInvest

Published: Aug. 28, 2025, 8:24 a.m.
Breakthrough designation for Genmab’s Rina-S in USA - The Pharma Letter

Breakthrough designation for Genmab’s Rina-S in USA The Pharma Letter

Published: Aug. 27, 2025, 6:11 p.m.
Elucidation of the mechanism of treating endometriosis with Ge Xia-Zhu Yu decoction by means of network pharmacology and molecular docking.

This study investigates the mechanism of Ge Xia-Zhu Yu decoction (GXZYT) in the treatment of endometriosis (EMS). The active components and targets of GXZYT were screened using TCMSP database and …

Published: Aug. 27, 2025, midnight
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer - CancerNetwork

Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork

Published: Aug. 26, 2025, 10:07 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!